JPS5686121A - Antitumor proten complex and its preparation - Google Patents

Antitumor proten complex and its preparation

Info

Publication number
JPS5686121A
JPS5686121A JP16160979A JP16160979A JPS5686121A JP S5686121 A JPS5686121 A JP S5686121A JP 16160979 A JP16160979 A JP 16160979A JP 16160979 A JP16160979 A JP 16160979A JP S5686121 A JPS5686121 A JP S5686121A
Authority
JP
Japan
Prior art keywords
antitumor
fragment
practically
component consisting
diphtheria toxin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP16160979A
Other languages
English (en)
Other versions
JPS6221000B2 (ja
Inventor
Naoji Umemoto
Yasuhiko Masuyasu
Takeshi Hara
Hidematsu Hirai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teijin Ltd
Original Assignee
Teijin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Ltd filed Critical Teijin Ltd
Priority to JP16160979A priority Critical patent/JPS5686121A/ja
Priority to DE8080304352T priority patent/DE3067584D1/de
Priority to EP80304352A priority patent/EP0031999B1/en
Priority to US06/216,709 priority patent/US4379145A/en
Publication of JPS5686121A publication Critical patent/JPS5686121A/ja
Publication of JPS6221000B2 publication Critical patent/JPS6221000B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6881—Cluster-antibody conjugates, i.e. the modifying agent consists of a plurality of antibodies covalently linked to each other or of different antigen-binding fragments covalently linked to each other
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP16160979A 1979-12-14 1979-12-14 Antitumor proten complex and its preparation Granted JPS5686121A (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP16160979A JPS5686121A (en) 1979-12-14 1979-12-14 Antitumor proten complex and its preparation
DE8080304352T DE3067584D1 (en) 1979-12-14 1980-12-03 Antitumor protein hybrid and process for the preparation thereof
EP80304352A EP0031999B1 (en) 1979-12-14 1980-12-03 Antitumor protein hybrid and process for the preparation thereof
US06/216,709 US4379145A (en) 1979-12-14 1980-12-15 Antitumor protein hybrid and process for the preparation thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP16160979A JPS5686121A (en) 1979-12-14 1979-12-14 Antitumor proten complex and its preparation

Publications (2)

Publication Number Publication Date
JPS5686121A true JPS5686121A (en) 1981-07-13
JPS6221000B2 JPS6221000B2 (ja) 1987-05-11

Family

ID=15738406

Family Applications (1)

Application Number Title Priority Date Filing Date
JP16160979A Granted JPS5686121A (en) 1979-12-14 1979-12-14 Antitumor proten complex and its preparation

Country Status (4)

Country Link
US (1) US4379145A (ja)
EP (1) EP0031999B1 (ja)
JP (1) JPS5686121A (ja)
DE (1) DE3067584D1 (ja)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6067434A (ja) * 1983-09-24 1985-04-17 Mitsubishi Chem Ind Ltd 抗腫瘍剤
JPS6069033A (ja) * 1983-06-21 1985-04-19 ザ・ボ−ド・オブ・リ−ジエンツ・ザ・ユニバ−シテイ・オブ・テキサス・システム 免疫毒素複合体
JPS6112630A (ja) * 1984-06-20 1986-01-21 サノフイ 免疫毒素およびその製造法
US7083957B2 (en) 2001-02-12 2006-08-01 Reasearch Development Foundation Modified proteins, designer toxins, and methods of making thereof
US7101977B2 (en) 2001-07-17 2006-09-05 Research Development Foundation Therapeutic agents comprising pro-apoptotic proteins

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8102194L (sv) * 1981-04-06 1982-10-07 Pharmacia Ab Terapeutiskt aktiv organisk forening och farmaceutisk beredning innehallande denna
SE8102193L (sv) * 1981-04-06 1982-10-07 Pharmacia Ab Terapeutiskt aktiv organisk forening och dess anvendning
ATE25197T1 (de) * 1982-05-12 1987-02-15 Harvard College Hybridproteinekodierende fusionierte gene, sie enthaltende klonierungsvektoren und deren verwendung.
US4487715A (en) * 1982-07-09 1984-12-11 The Regents Of The University Of California Method of conjugating oligopeptides
JPS59116232A (ja) * 1982-12-24 1984-07-05 Teijin Ltd 細胞毒性複合体及びその製造法
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
US4894443A (en) * 1984-02-08 1990-01-16 Cetus Corporation Toxin conjugates
EP0170697B1 (en) * 1984-02-08 1991-10-23 Cetus Oncology Corporation Toxin conjugates
US4625014A (en) * 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
US4698420A (en) * 1985-02-25 1987-10-06 Xoma Corporation Antibody hybrid molecules and process for their preparation
US4888415A (en) * 1985-03-04 1989-12-19 Dana-Farber Cancer Institute, Inc. Gelonin immunotoxin
WO1986005098A1 (en) * 1985-03-04 1986-09-12 Dana-Farber Cancer Institute, Inc. Immunotoxin and method of making
US5055291A (en) * 1986-11-04 1991-10-08 Baylor College Of Medicine Compositions for preventing secondary cataracts
US4871350A (en) * 1986-11-04 1989-10-03 Baylor College Of Medicine Methods and compositions for preventing secondary cataracts
US5827934A (en) * 1988-03-08 1998-10-27 The University Of Wyoming Cytotoxic diphtheria toxin fragments
US5171563A (en) * 1988-09-30 1992-12-15 Neorx Corporation Cleavable linkers for the reduction of non-target organ retention of immunoconjugates
GB9114399D0 (en) * 1991-07-03 1991-08-21 Ici Plc Conjugates
US5690935A (en) * 1995-01-13 1997-11-25 Regents Of The University Of Minnesota Biotherapy of cancer by targeting TP-3/P80
US6050943A (en) 1997-10-14 2000-04-18 Guided Therapy Systems, Inc. Imaging, therapy, and temperature monitoring ultrasonic system
US7914453B2 (en) 2000-12-28 2011-03-29 Ardent Sound, Inc. Visual imaging system for ultrasonic probe
AU2003295520B8 (en) * 2002-11-12 2011-05-19 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for Staphylococcal infections
US9011336B2 (en) * 2004-09-16 2015-04-21 Guided Therapy Systems, Llc Method and system for combined energy therapy profile
US7393325B2 (en) 2004-09-16 2008-07-01 Guided Therapy Systems, L.L.C. Method and system for ultrasound treatment with a multi-directional transducer
US7824348B2 (en) 2004-09-16 2010-11-02 Guided Therapy Systems, L.L.C. System and method for variable depth ultrasound treatment
US7530958B2 (en) * 2004-09-24 2009-05-12 Guided Therapy Systems, Inc. Method and system for combined ultrasound treatment
US8535228B2 (en) 2004-10-06 2013-09-17 Guided Therapy Systems, Llc Method and system for noninvasive face lifts and deep tissue tightening
US8444562B2 (en) 2004-10-06 2013-05-21 Guided Therapy Systems, Llc System and method for treating muscle, tendon, ligament and cartilage tissue
US10864385B2 (en) 2004-09-24 2020-12-15 Guided Therapy Systems, Llc Rejuvenating skin by heating tissue for cosmetic treatment of the face and body
US7758524B2 (en) 2004-10-06 2010-07-20 Guided Therapy Systems, L.L.C. Method and system for ultra-high frequency ultrasound treatment
US9827449B2 (en) 2004-10-06 2017-11-28 Guided Therapy Systems, L.L.C. Systems for treating skin laxity
US20060111744A1 (en) 2004-10-13 2006-05-25 Guided Therapy Systems, L.L.C. Method and system for treatment of sweat glands
US8690778B2 (en) 2004-10-06 2014-04-08 Guided Therapy Systems, Llc Energy-based tissue tightening
US7530356B2 (en) * 2004-10-06 2009-05-12 Guided Therapy Systems, Inc. Method and system for noninvasive mastopexy
KR20110091828A (ko) 2004-10-06 2011-08-12 가이디드 테라피 시스템스, 엘.엘.씨. 미용 초음파 치료 시스템
ES2747361T3 (es) * 2004-10-06 2020-03-10 Guided Therapy Systems Llc Procedimiento para la mejora cosmética no invasiva de la celulitis
US11883688B2 (en) 2004-10-06 2024-01-30 Guided Therapy Systems, Llc Energy based fat reduction
US11235179B2 (en) 2004-10-06 2022-02-01 Guided Therapy Systems, Llc Energy based skin gland treatment
US9694212B2 (en) 2004-10-06 2017-07-04 Guided Therapy Systems, Llc Method and system for ultrasound treatment of skin
US8133180B2 (en) 2004-10-06 2012-03-13 Guided Therapy Systems, L.L.C. Method and system for treating cellulite
US11724133B2 (en) 2004-10-07 2023-08-15 Guided Therapy Systems, Llc Ultrasound probe for treatment of skin
US11207548B2 (en) 2004-10-07 2021-12-28 Guided Therapy Systems, L.L.C. Ultrasound probe for treating skin laxity
EP2533130A1 (en) 2005-04-25 2012-12-12 Ardent Sound, Inc. Method and system for enhancing computer peripheral saftey
US9566454B2 (en) * 2006-09-18 2017-02-14 Guided Therapy Systems, Llc Method and sysem for non-ablative acne treatment and prevention
US20150174388A1 (en) 2007-05-07 2015-06-25 Guided Therapy Systems, Llc Methods and Systems for Ultrasound Assisted Delivery of a Medicant to Tissue
US9216276B2 (en) * 2007-05-07 2015-12-22 Guided Therapy Systems, Llc Methods and systems for modulating medicants using acoustic energy
CA3128656A1 (en) 2007-08-22 2009-02-26 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof
KR20110020293A (ko) 2008-06-06 2011-03-02 얼테라, 인크 코스메틱 치료 및 이미징 시스템 및 방법
RU2532911C2 (ru) 2008-07-21 2014-11-20 Дзе Брихэм Энд Уимен'З Хоспитал, Инк. Способы и композиции, относящиеся к синтетическим бета-1,6-глюкозаминолигосахаридам
EP2382010A4 (en) 2008-12-24 2014-05-14 Guided Therapy Systems Llc METHOD AND SYSTEMS FOR FAT REDUCTION AND / OR TREATMENT OF CELLULITE
JP5851842B2 (ja) 2009-01-12 2016-02-03 サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. 改変した抗体組成物、それを作製および使用する方法
AU2010215761B2 (en) * 2009-02-23 2017-04-06 Cytomx Therapeutics, Inc Proproteins and methods of use thereof
US8715186B2 (en) 2009-11-24 2014-05-06 Guided Therapy Systems, Llc Methods and systems for generating thermal bubbles for improved ultrasound imaging and therapy
EP2600783A4 (en) 2010-08-02 2017-05-17 Guided Therapy Systems, L.L.C. Systems and methods for ultrasound treatment
US9504446B2 (en) 2010-08-02 2016-11-29 Guided Therapy Systems, Llc Systems and methods for coupling an ultrasound source to tissue
US8857438B2 (en) 2010-11-08 2014-10-14 Ulthera, Inc. Devices and methods for acoustic shielding
WO2013009785A2 (en) 2011-07-10 2013-01-17 Guided Therapy Systems, Llc. Systems and methods for improving an outside appearance of skin using ultrasound as an energy source
KR20190080967A (ko) 2011-07-11 2019-07-08 가이디드 테라피 시스템스, 엘.엘.씨. 조직에 초음파원을 연결하는 시스템 및 방법
US9263663B2 (en) 2012-04-13 2016-02-16 Ardent Sound, Inc. Method of making thick film transducer arrays
US9510802B2 (en) 2012-09-21 2016-12-06 Guided Therapy Systems, Llc Reflective ultrasound technology for dermatological treatments
CN113648551A (zh) 2013-03-08 2021-11-16 奥赛拉公司 用于多焦点超声治疗的装置和方法
WO2014146022A2 (en) 2013-03-15 2014-09-18 Guided Therapy Systems Llc Ultrasound treatment device and methods of use
EP3131630B1 (en) 2014-04-18 2023-11-29 Ulthera, Inc. Band transducer ultrasound therapy
FI3405294T3 (fi) 2016-01-18 2023-03-23 Ulthera Inc Pienikokoinen ultraäänilaite, jossa on renkaan muotoinen ultraääniryhmä, joka on yhdistetty sähköisesti reunalle taipuisaan piirilevyyn
DK3981466T3 (da) 2016-08-16 2023-10-09 Ulthera Inc Systemer og fremgangsmåder til kosmetisk ultralydsbehandling af hud
WO2019164836A1 (en) 2018-02-20 2019-08-29 Ulthera, Inc. Systems and methods for combined cosmetic treatment of cellulite with ultrasound

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2862449D1 (en) * 1977-08-22 1984-11-22 Nat Res Dev Macromolecular covalent conjugates, methods for preparing and pharmaceutical compositions containing them
JPS54145655A (en) * 1978-05-06 1979-11-14 Asahi Chem Ind Co Ltd Imidate derivative and its salt
JPS54145656A (en) * 1978-05-06 1979-11-14 Asahi Chem Ind Co Ltd Alkoxyvinyl ester compound
JPS55136235A (en) * 1979-04-09 1980-10-23 Teijin Ltd Antitumor protein complex and its preparation
JPS5616417A (en) * 1979-07-19 1981-02-17 Teijin Ltd Antitumor protein complex and its preparation
JPS5616418A (en) * 1979-07-20 1981-02-17 Teijin Ltd Antitumor protein complex and its preparation

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6069033A (ja) * 1983-06-21 1985-04-19 ザ・ボ−ド・オブ・リ−ジエンツ・ザ・ユニバ−シテイ・オブ・テキサス・システム 免疫毒素複合体
JPS6067434A (ja) * 1983-09-24 1985-04-17 Mitsubishi Chem Ind Ltd 抗腫瘍剤
JPH0585532B2 (ja) * 1983-09-24 1993-12-07 Mitsubishi Chem Ind
JPS6112630A (ja) * 1984-06-20 1986-01-21 サノフイ 免疫毒素およびその製造法
US7285635B2 (en) 2001-02-12 2007-10-23 Research Development Foundation Modified proteins, designer toxins, and methods of making thereof
US7083957B2 (en) 2001-02-12 2006-08-01 Reasearch Development Foundation Modified proteins, designer toxins, and methods of making thereof
US7741278B2 (en) 2001-02-12 2010-06-22 Research Development Foundation Modified proteins, designer toxins, and methods of making thereof
US7943571B2 (en) 2001-02-12 2011-05-17 Research Development Foundation Modified proteins, designer toxins, and methods of making thereof
US8138311B2 (en) 2001-02-12 2012-03-20 Research Development Foundation Modified proteins, designer toxins, and methods of making thereof
US7101977B2 (en) 2001-07-17 2006-09-05 Research Development Foundation Therapeutic agents comprising pro-apoptotic proteins
US7371723B2 (en) 2001-07-17 2008-05-13 Research Development Foundation Therapeutic agents comprising pro-apoptotic proteins
US7759091B2 (en) 2001-07-17 2010-07-20 Research Development Foundation Therapeutic agents comprising pro-apoptotic proteins
US8043831B2 (en) 2001-07-17 2011-10-25 Research Development Foundation Therapeutic agents comprising pro-apoptotic proteins

Also Published As

Publication number Publication date
DE3067584D1 (en) 1984-05-24
JPS6221000B2 (ja) 1987-05-11
EP0031999A2 (en) 1981-07-15
EP0031999B1 (en) 1984-04-18
EP0031999A3 (en) 1981-07-29
US4379145A (en) 1983-04-05

Similar Documents

Publication Publication Date Title
JPS5686121A (en) Antitumor proten complex and its preparation
JPS5616418A (en) Antitumor protein complex and its preparation
DE3372175D1 (en) Covalent conjugates of an enzyme and an antibody, and medicinal compositions containing these conjugates
IL47372A (en) Fab'dimers bound to daunomycin or adriamycin,their preparation and pharmaceutical compositions containing same
JPS55136235A (en) Antitumor protein complex and its preparation
PT73291A (en) Process for the preparation of novel peptides
JPS5616417A (en) Antitumor protein complex and its preparation
PT73950B (fr) Procede de preparation de composes de dichloredietilaminopheni-lalanine d'action antitumureuse
ZA864769B (en) Process and composition for treatment of cancer and non-malignant tumors
JPS5225772A (en) Preparation of molecular compound of allantoin and ornithine
WO1991019725A3 (en) Heterocyclic anthracyclione and anthracycline analogs
JPS5764617A (en) Cytotoxic proteinic complex and its preparation
JPS55135135A (en) Production of polyoxyalkylene polyether having organosiloxane linkage at end of molecular chain
JPS5592325A (en) Antitumor agent and its preparation
JPS5446776A (en) Novel peptide
ES8300780A1 (es) Procedimiento para preparar oxido de bis(cloroetil-butilestano)
ES456118A1 (es) Procedimiento para la preparacion de un compuesto entre un polimero sintetico que contiene grupos hidroxilo vecinos, y una sustancia que contiene grupos amino primarios.
JPS5347455A (en) Chaff compositions
JPS51140211A (en) Body frame for all-closed electric compresser
JPS5276346A (en) Epoxy resin adhesive composition
JPS52122612A (en) Anti-tumor substance and its preparation
JPS5214712A (en) Preparation of 2-amino-2-deoxy-d-ribose
JPS5211938A (en) Prism
JPS5271489A (en) Synthesis of josamycin derivative
JPS5248601A (en) Process for preparation of amino acids